Adviezen commissie BOM

Terug naar lijst
  • Auteur
  • NVMO-commissie BOM
  • Printdatum
  • 14-3-2001
  • E-pubdatum
  • 14-3-2001
  • Bron
  • Medische Oncologie

Raltitrexed bij colorectaal carcinoom

In vergelijking met de standaardbehandeling met 5FU/LV heeft raltitrexed geen meerwaarde.

Referenties

  1. Zalcberg JR, Cunningham D, Van Cutsem E, Francois E, Schornagel J, Adenis A, Green M, Iveson A, Azab M and Seymour J. ZD 1694: a novel thymidilate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol 1996; 14: 716-721.
  2. Cunningham D, Zalcberg JR, Rath U, Oliver J, Van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G, and the Tomudex® Colorectal Cancer Study Group. Final results of a randomised trial comparing Tomudex (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 1996; 7: 961-965.
  3. Pazdur R, Vincent M. Raltitrexed (Tomudex) vs 5-fluorouracil + leucovorin in patients with advanced colorectal cancer: results of a randomised multicenter North American trial. Proc Am Soc Clin Oncol 1997; 16: 228a.
  4. Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, Van Hazel G, Kerr D, Possinger K, Hietschold SM. on behalf of the Tomudex® Colorectal Cancer Study Group. Open randomized multicenter trial of raltitrexed versus fluorouracil plus leucovorin in patients with advanced colorectal cancer. J Clin Oncol 1998; 16.
  5. The Lancet. Drug company decision to end cancer trial 1999; 354: 1045.
  6. Maughan T, James R, Kerr D, Ledermann J, McArdle C, Seymour M, Johnston C, Stephens R. Excess treatment related deaths and impaired quality of life show raltitrexed is inferior to infusional 5FU regimens in the palliative chemotherapy of advanced colorectal cancer (CRC): Final results of MRC CR06. Ann Oncol 2000 11: 43 S.